Photo from wikipedia
Patients with type 2 diabetes mellitus have a higher bone fracture risk than patients without diabetes. Although denosumab (Dmab) is a potent bone resorption inhibitor, its efficacy in patients with… Click to show full abstract
Patients with type 2 diabetes mellitus have a higher bone fracture risk than patients without diabetes. Although denosumab (Dmab) is a potent bone resorption inhibitor, its efficacy in patients with type 2 diabetes mellitus has not been elucidated. In this study, we investigated the effects of switching to Dmab from bisphosphonates (BP) or a selective estrogen receptor modulator (SERM) in postmenopausal type 2 diabetes mellitus patients.
Keywords:
selective estrogen;
effects switching;
denosumab;
type diabetes;
bisphosphonates selective;
estrogen receptor
Journal Title: Journal of Diabetes Investigation
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Diabetes Investigation
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!